Cidara Therapeutics Inc (NASDAQ: CDTX) is -27.68% lower on its value in year-to-date trading and has touched a low of $10.00 and a high of $28.42 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The CDTX stock was last observed hovering at around $19.18 in the last trading session, with the day’s gains setting it 0.26%.
Currently trading at $19.44, the stock is -0.25% and -9.18% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.11 million and changing 1.36% at the moment leaves the stock 15.56% off its SMA200. CDTX registered 33.15% gain for a year compared to 6-month gain of 91.15%. The firm has a 50-day simple moving average (SMA 50) of $21.406 and a 200-day simple moving average (SMA200) of $16.82192.
The stock witnessed a -14.55% loss in the last 1 month and extending the period to 3 months gives it a -8.52%, and is 13.75% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 6.47% over the week and 8.33% over the month.
Cidara Therapeutics Inc (CDTX) has around 38 employees, a market worth around $212.94M and $8.77M in sales. Profit margin for the company is -1917.03%. Distance from 52-week low is 94.32% and -31.60% from its 52-week high. The company has generated returns on investments over the last 12 months (-101.69%).
The EPS is expected to grow by 61.90% this year, but quarterly earnings will post -100.00% year-over-year. Quarterly sales are estimated to shrink -100.00% in year-over-year returns.
50.0 institutions hold shares in Cidara Therapeutics Inc (CDTX), with institutional investors hold 70.45% of the company’s shares. The shares outstanding are 10.95M, and float is at 6.82M with Short Float at 6.90%. Institutions hold 69.48% of the Float.
The top institutional shareholder in the company is MONASHEE INVESTMENT MANAGEMENT LLC with over 0.37 million shares valued at $4.41 million. The investor’s holdings represent 8.0876 of the CDTX Shares outstanding. As of 2024-06-30, the second largest holder is BVF INC/IL with 0.34 million shares valued at $4.1 million to account for 7.5169 of the shares outstanding. The other top investors are CHECKPOINT CAPITAL L.P. which holds 0.15 million shares representing 3.1863 and valued at over $1.74 million, while RENAISSANCE TECHNOLOGIES LLC holds 2.0929 of the shares totaling 95517.0 with a market value of $1.14 million.
Cidara Therapeutics Inc (CDTX) Insider Activity
The most recent transaction is an insider sale by Ward Shane, the company’s COO & CLO. SEC filings show that Ward Shane sold 1,664 shares of the company’s common stock on Mar 11 ’25 at a price of $21.96 per share for a total of $36542.0. Following the sale, the insider now owns 14674.0 shares.
Cidara Therapeutics Inc disclosed in a document filed with the SEC on Mar 11 ’25 that Tari Leslie (CHIEF SCIENTIFIC OFFICER) sold a total of 1,773 shares of the company’s common stock. The trade occurred on Mar 11 ’25 and was made at $21.96 per share for $38940.0. Following the transaction, the insider now directly holds 16215.0 shares of the CDTX stock.
Still, SEC filings show that on Sep 11 ’24, Sandison Taylor (Chief Medical Officer) disposed off 924 shares at an average price of $11.64 for $10752.0. The insider now directly holds 23,067 shares of Cidara Therapeutics Inc (CDTX).
